Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 16:6:54.
doi: 10.1038/s41523-020-00197-2. eCollection 2020.

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies

Antonio Marra  1   2 , Dario Trapani  1 , Giulia Viale  1 , Carmen Criscitiello  1 , Giuseppe Curigliano  1   2
Affiliations
Review

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies

Antonio Marra et al. NPJ Breast Cancer. .

Abstract

Triple-negative breast cancer (TNBC) is not a unique disease, encompassing multiple entities with marked histopathological, transcriptomic and genomic heterogeneity. Despite several efforts, transcriptomic and genomic classifications have remained merely theoretic and most of the patients are being treated with chemotherapy. Driver alterations in potentially targetable genes, including PIK3CA and AKT, have been identified across TNBC subtypes, prompting the implementation of biomarker-driven therapeutic approaches. However, biomarker-based treatments as well as immune checkpoint inhibitor-based immunotherapy have provided contrasting and limited results so far. Accordingly, a better characterization of the genomic and immune contexture underpinning TNBC, as well as the translation of the lessons learnt in the metastatic disease to the early setting would improve patients' outcomes. The application of multi-omics technologies, biocomputational algorithms, assays for minimal residual disease monitoring and novel clinical trial designs are strongly warranted to pave the way toward personalized anticancer treatment for patients with TNBC.

Keywords: Breast cancer.

PubMed Disclaimer

Conflict of interest statement

Competing interestsC.C. received speakers’ bureau and consultancy/advisory role from Lilly, Roche Novartis, and Pfizer. G.C. reports personal fees for consulting, advisory role and speakers’ bureau from Roche/Genentech, Novartis, Pfizer, Lilly, Foundation Medicine, Samsung, and Daichii-Sankyo; honoraria from Ellipses Pharma; fees for travel and accommodations from Roche/Genentech, and Pfizer. The remaining authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Triple-negative breast cancer molecular subtypes across studies.
Transcriptomic-based and gene expression-based subtypes of triple-negative breast cancer (TNBC) according to PAM50 (a) and defined by Lehmann et al., (b and d), Curtis et al. (c), Burstein et al. (e), and Jiang et al. (f). BLIA basal-like immune-activated, BLIS basal-like immunosuppressed, BL1 basal-like 1, BL2 basal-like 2, IM immunomodulatory, IntClust integrative clusters, LAR luminal androgen receptor, M mesenchymal, MES mesenchymal, MSL mesenchymal stem-like, UNS unstable. Figures was generated by reanalysis of publicly available studies and open-source platforms (cBioPortal: https://www.cbioportal.org).
Fig. 2
Fig. 2
Biomarker-driven therapeutic approaches in triple-negative breast cancer.
See this image and copyright information in PMC

References

    1. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N. Engl. J. Med. 2010;363:1938–1948. doi: 10.1056/NEJMra1001389. - DOI - PubMed
    1. Perou CM, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752. doi: 10.1038/35021093. - DOI - PubMed
    1. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J. Clin. Oncol. 2008;26:2568–2581. doi: 10.1200/JCO.2007.13.1748. - DOI - PubMed
    1. Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9:176–198. doi: 10.1158/2159-8290.CD-18-1177. - DOI - PMC - PubMed
    1. Bertucci F, et al. How basal are triple-negative breast cancers? Int. J. Cancer. 2008;123:236–240. doi: 10.1002/ijc.23518. - DOI - PubMed